Results for keyword - Nutritional Supplement

Herbalife Ltd. Announces Record First Quarter 2011 Results and Raises FY’11 Guidance

Tuesday, May 3rd, 2011

hlf2

- First quarter net sales growth of 28.5 percent on volume growth of 21.5 percent.

- First quarter adjusted1 EPS of $1.43 increased 45.9 percent compared to the $0.98 adjusted1 EPS from prior year period.

- Raises FY’11 EPS guidance to a range of $5.54 to $5.78.

- Shareholders approve 2 for 1 stock split with a record date May 10, 2011.

- Board of directors approved a post stock-split quarterly dividend of $0.20 per share.

LOS ANGELES–(CRWENewswire May 2, 2011)– Herbalife Ltd. (NYSE:HLF) today reported that first quarter net sales increased 28.5 percent and local currency net sales increased 24.7 percent compared to the same time period in 2010. Adjusted1 net income for the quarter of $88.3 million, or $1.43 per diluted share compares to 2010 first quarter adjusted net income and EPS of $61.5 million and $0.98, respectively. On a reported basis, first quarter 2011 EPS of $1.41 increased 70 percent compared to the $0.83 reported in the comparable quarter last year.

“Our ongoing efforts to globalize daily consumption-based distributor methods of operation (DMOs) continued to provide strong growth to both the top and bottom line growth in the first quarter,” said Michael O. Johnson, the company’s chairman and CEO. “The company’s strategic focus to provide solutions for two large mega trends, the global obesity epidemic and the desire for people to earn more income, continues to provide a large platform for us to succeed. The company will continue to invest to support our growth with such initiatives as the Seed to Feed verticalization strategy.”

For the quarter ended March 31, 2011, the company generated cash flow from operations of $107.5 million, an increase of 23.0 percent compared to the first quarter 2010, paid dividends of $14.8 million and invested $28.3 million in capital expenditures.

_______________________
1 See Schedule B – “Reconciliation of Non-GAAP Financial Measures” for more detail.

First Quarter 2011 Regional Key Metrics2,3

Regional Volume Point and Average Active Sales Leader Metrics


	Volume Points (Mil)			Average Active Sales Leaders
Region	1Q’11	Yr/Yr % Chg		1Q’11	Yr/Yr % Chg
North America	243.0	10.4	%	52,549	14.7	%
Asia Pacific	198.7	30.6	%	40,510	27.0	%
EMEA	138.0	15.5	%	35,960	12.2	%
Mexico	164.5	32.4	%	42,480	23.2	%
South & Central America	125.1	23.7	%	30,970	13.8	%
China	32.8	28.1	%	7,272	36.7	%
Worldwide Total	902.1	21.5	%	205,036	20.8	%


	Volume Points (Mil)			Average Active Sales Leaders
	1Q’11	Yr/Yr % Chg		1Q’11	Yr/Yr % Chg
Emerging Markets	475.2	29.1	%	113,176	25.8	%
Established Markets	426.9	14.0	%	95,392	16.2	%
Worldwide Total	902.1	21.5	%	205,036	20.8	%

_______________________
2 “Emerging markets” are defined herein as those countries that the World Bank categorized as having “low” or “medium” GDP per capita, while “Established markets” are defined as those countries categorized by the World Bank as having “high” GDP per capita.
3
Supplemental tables that include additional business metrics can be found at http://www.ir.herbalife.com

Updated 2011 Guidance

Based on current business trends and foreign currency rates, the company’s second quarter and fiscal 2011 guidance is provided below.

Second Quarter – The company’s second quarter 2011 diluted, pre-split earnings per share guidance range is $1.42 to $1.48 on volume point growth of 10.0 percent to 12.0 percent and net sales growth of 19.0 percent to 21.0 percent compared to the same period in 2010, respectively, and an effective tax rate range of 28.3 percent to 29.3 percent. The company’s second quarter 2011 capital expenditures are expected to be in the range of $18.0 million to $23.0 million.

Fiscal 2011 – The company’s fiscal 2011 diluted, pre-split earnings per share guidance range is $5.54 to $5.78 on volume point growth of 12.0 percent to 14.0 percent and net sales growth of 18.0 percent to 20.0 percent compared to the same period in 2010, respectively, and an effective tax rate range of 28.0 percent to 29.0 percent. The company’s fiscal 2011 capital expenditures are expected to be in the range of $80.0 million to $90.0 million.

Shareholders Approved Stock Split

As reported, the two-for-one stock split previously approved by the Herbalife board of directors was approved by the shareholders on April 28, 2011. The stock split will go into effect by the subdivision of each outstanding Common Share of a par value of $0.002 each into two Common Shares of a par value of $0.001 each and a proportional amendment of the authorized share capital. The record date for the stock split will be May 10, 2011. Each shareholder of record as of the close of business on the record date will receive one additional Common Share for every share held. The new shares will be distributed on or about May 17, 2011.

Announces Quarterly Dividend

The company reported today that its board of directors has approved a post-stock split dividend of $0.20 per share to shareholders of record effective May 24, 2011 payable on June 7, 2011.

First Quarter Earnings Conference Call

Herbalife’s senior management will host an investor conference call to discuss its recent financial results and provide an update on current business trends on Tuesday, May 3, 2011 at 8 a.m. PDT (11 a.m. EDT).

The dial-in number for this conference call for domestic callers is (877) 317-1296 and (706) 634-5671 for international callers (conference ID 57487434). Live audio of the conference call will be simultaneously webcast in the investor relations section of the company’s website at http://ir.herbalife.com.

An audio replay will be available following the completion of the conference call in MP3 format or by dialing (800) 642-1687 for domestic callers or (706) 645-9291 for international callers (conference ID 57487434). The webcast of the teleconference will be archived and available on Herbalife’s website.

About Herbalife Ltd.

Herbalife Ltd. (NYSE:HLF) is a global network marketing company that sells weight-management, nutrition, and personal care products intended to support a healthy lifestyle. Herbalife products are sold in 75 countries through a network of approximately 2.3 million independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife’s website contains a significant amount of information about Herbalife, including financial and other information for investors at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted.

FORWARD-LOOKING STATEMENTS

This document contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” and any other similar words.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, such as those disclosed or incorporated by reference in our filings with the Securities and Exchange Commission. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in our forward-looking statements include, among others, the following:

* any collateral impact resulting from the ongoing worldwide financial “crisis,” including the availability of liquidity to us, our customers and our suppliers or the willingness of our customers to purchase products in a recessionary economic environment;

* our relationship with, and our ability to influence the actions of, our distributors;

* improper action by our employees or distributors in violation of applicable law;

* adverse publicity associated with our products or network marketing organization;

* changing consumer preferences and demands;

* our reliance upon, or the loss or departure of any member of, our senior management team which could negatively impact our distributor relations and operating results;

* the competitive nature of our business;

* regulatory matters governing our products, including potential governmental or regulatory actions concerning the safety or efficacy of our products and network marketing program, including the direct selling market in which we operate;

* legal challenges to our network marketing program;

* risks associated with operating internationally and the effect of economic factors, including foreign exchange, inflation, disruptions or conflicts with our third party importers, pricing and currency devaluation risks, especially in countries such as Venezuela;

* uncertainties relating to the application of transfer pricing, duties, value added taxes, and other tax regulations, and changes thereto;

* uncertainties relating to interpretation and enforcement of recently enacted legislation in China governing direct selling;

* our inability to obtain the necessary licenses to expand our direct selling business in China;

* adverse changes in the Chinese economy, Chinese legal system or Chinese governmental policies;

* our dependence on increased penetration of existing markets;

* contractual limitations on our ability to expand our business;

* our reliance on our information technology infrastructure and outside manufacturers;

* the sufficiency of trademarks and other intellectual property rights;

* product concentration;

* changes in tax laws, treaties or regulations, or their interpretation;

* taxation relating to our distributors;

* product liability claims; and

* whether we will purchase any of our shares in the open markets or otherwise.

We do not undertake any obligation to update or release any revisions to any forward-looking statements or report any events or circumstances after the date hereof or to reflect the occurrences of unanticipated events, except as required by law.

RESULTS OF OPERATIONS:


Herbalife Ltd.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

	Quarter Ended
	3/31/2011		3/31/2010

North America	$	167,000	$	151,259
Mexico		103,877		71,849
South and Central America		125,277		91,330
EMEA		153,937		130,824
Asia Pacific		199,303		141,013
China		45,702		32,358
Worldwide net sales		795,096		618,633
Cost of Sales		162,793		140,472	¹
Gross Profit		632,303		478,161
Royalty Overrides		264,377		207,319
SGA		244,526		206,883	¹
Operating Income		123,400		63,959
Interest Expense - net		2,648		1,953
Income before income taxes		120,752		62,006
Income Taxes		33,184		10,135	¹
Net Income		87,568		51,871

Basic Shares		59,103		60,160
Diluted Shares		61,908		62,672

Basic EPS	$	1.48	$	0.86
Diluted EPS	$	1.41	$	0.83

Dividends declared per share	$	0.25	$	0.20

¹		Includes impact of items related to adoption of highly-inflationary accounting in Venezuela that are further discussed in Schedule B – “Reconciliation of Non-GAAP Financial Measures”



Herbalife Ltd.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)

	Mar 31,			Dec 31,
	2011			2010

ASSETS
Current Assets:
Cash & cash equivalents	$	260,766		$	190,550
Receivables, net		107,893			85,612
Inventories		184,321			182,467
Prepaid expenses and other current assets		110,400			93,963
Deferred income taxes		42,355			42,994
Total Current Assets		705,735			595,586

Property and equipment, net		187,733			177,427
Deferred compensation plan assets		18,732			18,536
Deferred financing cost, net		5,451			998
Other assets		26,639			25,880
Marketing related intangibles and other and other intangible assets, net		310,815			310,894
Goodwill		102,899			102,899
Total Assets	$	1,358,004		$	1,232,220


LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	53,725		$	43,784
Royalty Overrides		173,076			162,141
Accrued compensation		52,540			69,376
Accrued expenses		138,523			141,867
Current portion of long term debt		1,753			3,120
Advance sales deposits		56,928			35,145
Income taxes payable		18,340			15,383
Total Current Liabilities		494,885			470,816

Non-current liabilities
Long-term debt, net of current portion		181,188			175,046
Deferred compensation		23,197			20,167
Deferred income taxes		55,220			55,572
Other non-current liabilities		23,216			23,407
Total Liabilities		777,706			745,008

Contingencies

Shareholders’ equity:
Common shares		119			118
Additional paid in capital		262,617			257,375
Accumulated other comprehensive loss		(12,074	)		(27,285	)
Retained earnings		329,636			257,004
Total Shareholders’ Equity		580,298			487,212

Total Liabilities and Shareholders’ Equity	$	1,358,004		$	1,232,220



Herbalife Ltd.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Quarter Ended
	3/31/2011			3/31/2010

CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	87,568		$	51,871
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		18,562			17,262
(Excess) Deficiency in tax benefits from share-based payment arrangements		(6,794	)		(2,606	)
Share-based compensation expenses		5,604			5,295
Amortization of discount and deferred financing costs		149			124
Deferred income taxes		921			(13,671	)
Unrealized foreign exchange transaction (gain) loss		1,383			(2,608	)
Write-off of deferred financing costs		914			—
Foreign exchange loss from adoption of highly inflationary accounting in Venezuela		—			15,131
Other		751			1,078
Changes in operating assets and liabilities:
Receivables		(20,493	)		(12,048	)
Inventories		4,184			474
Prepaid expenses and other current assets		(13,582	)		(4,357	)
Other assets		(251	)		(71	)
Accounts payable		8,861			19,311
Royalty overrides		7,340			(7,081	)
Accrued expenses and accrued compensation		(21,122	)		(14,022	)
Advance sales deposits		20,998			26,741
Income taxes payable		9,494			5,566
Deferred compensation plan liability		3,030			1,044
NET CASH PROVIDED BY OPERATING ACTIVITIES		107,517			87,433
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property		(28,325	)		(11,623	)
Proceeds from sale of property		2			3
Deferred compensation plan assets		(197	)		(79	)
NET CASH USED IN INVESTING ACTIVITIES		(28,520	)		(11,699	)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid		(14,819	)		(12,065	)
Borrowings from long-term debt		289,700			102,000
Principal payments on long-term debt		(284,924	)		(104,951	)
Deferred financing costs		(5,516	)		—
Share repurchases		(8,965	)		(28,010	)
Excess (Deficiency in) tax benefits from share-based payment arrangements		6,794			2,606
Proceeds from exercise of stock options and sale of stock under employee stock purchase plan		1,689			1,888
NET CASH USED IN FINANCING ACTIVITIES		(16,041	)		(38,532	)
EFFECT OF EXCHANGE RATE CHANGES ON CASH		7,260			(22,732	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		70,216			14,470
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		190,550			150,801
CASH AND CASH EQUIVALENTS, END OF PERIOD		260,766			165,271
CASH PAID DURING THE PERIOD
Interest paid	$	2,093		$	2,691
Income taxes paid, net	$	21,874		$	13,430

SUPPLEMENTAL INFORMATION

Schedule A: Financial Guidance

2011 Guidance

For the Three Months Ending June 30, 2011 and Twelve Months Ending December 31, 2011


	Three Months Ending June 30, 2011						Twelve Months Ending December 31, 2011
	Low			High			Low			High
Volume point growth vs 2010		10.0	%		12.0	%		12.0	%		14.0	%
Net sales growth vs 2010		19.0	%		21.0	%		18.0	%		20.0	%
EPS - Pre Stock Split	$	1.42		$	1.48		$	5.54		$	5.78
EPS - Post Stock Split	$	0.71		$	0.74		$	2.77		$	2.89
Cap Ex ($ millions)	$	18.0		$	23.0		$	80.0		$	90.0
Effective Tax Rate		28.3	%		29.3	%		28.0	%		29.0	%

SCHEDULE B: RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(unaudited), (Dollars in Thousand, Except Per Share Data)

In addition to its reported results, the Company has included in the tables below adjusted results that the Securities and Exchange Commission defines as “non-GAAP financial measures.” Management believes that such non-GAAP financial measures, when read in conjunction with the Company’s reported results, can provide useful supplemental information for investor in analyzing period to period comparisons of the Company’s results.

The following is a reconciliation of net income and diluted earnings per share, presented and reported in accordance with U.S. generally accepted accounting principles, to net income adjusted for certain items:


Herbalife Ltd.
Supplemental Schedule
Non-GAAP Financial Measures
(In thousands, except per share data)
(Unaudited)

	Quarter Ended 3/31/2011
	Reported						Adjusted
	(GAAP)		Adjustment				(Non-GAAP)
Net Sales		795,096						795,096
Cost of Sales		162,793						162,793
Gross Profit		632,303		-				632,303
Royalty Overrides		264,377						264,377
SGA		244,526						244,526
Operating Income		123,400		-				123,400
Interest Expense - net		2,648		(914	)	¹		1,734
Income before income taxes		120,752		914				121,666
Income Taxes		33,184		214		¹		33,398
Net Income		87,568		700				88,268

Diluted EPS	$	1.41	$	0.01			$	1.43	²

¹		Write-off of unamortized deferred financing costs resulting from the debt refinancing arrangement in March 2011.
²		Amounts may not total due to rounding.



Herbalife Ltd.
Supplemental Schedule
Non-GAAP Financial Measures
(In thousands, except per share data)
(Unaudited)

	Quarter Ended 3/31/2010
	Reported		Venezuela				Adjusted
	(GAAP)		Items				(Non-GAAP)
Net Sales		618,633						618,633
Cost of Sales		140,472		(12,715	)	¹		127,757
Gross Profit		478,161		12,715				490,876
Royalty Overrides		207,319						207,319
SGA		206,883		(11,390	)	²		195,493
Operating Income		63,959		24,105				88,064
Interest Expense - net		1,953						1,953
Income before income taxes		62,006		24,105				86,111
Income Taxes		10,135		14,452		³		24,587
Net Income		51,871		9,653				61,524

Diluted EPS	$	0.83	$	0.15			$	0.98

¹		Incremental U.S. dollar costs of 2009 imports which were recorded at the unfavorable parallel market exchange rate and were not devalued based on 2010 exchange rates but rather recorded at their historical dollar costs as products were sold
²		Includes $15,131 foreign exchange loss related to remeasurement of Venezuela’s monetary assets and liabilities resulting from adoption of highly inflationary accounting and $3,741 foreign exchange gain resulting from receipt of U.S. dollar approved by CADIVI at the official exchange rate relating to 2009 product importations which were previously registered with CADIVI
³		Favorable income taxes related to Venezuela becoming highly inflationary economy

The following is a reconciliation of total long-term debt to net debt:


	3/31/2011			12/31/2010

Total long-term debt (current and long-term portion)	$	182,941		$	178,166
Less: Cash and cash equivalents		260,766			190,550
Net debt	$	(77,825	)	$	(12,384	)

Contact:

Herbalife Ltd.
Media Contact:
Barbara Henderson
SVP, Worldwide Corp. Comm.
213.745.0517

or

Investor Contact:
Amy Greene
VP, Investor Relations
213.745.0474

Source: Herbalife Ltd.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Tags: fitness, Herbalife, HLF, nutritional supplement, NYSE:HLF, targeted nutrition, weight management

Posted in Stock Alerts |

MusclePharm Appoints Former Bristol-Myers Squibb Executive as Director of Therapeutic Nutrition

Wednesday, December 15th, 2010

Company Further Enhances Strength of Scientific Development & Research Team

DENVER, Dec. 15, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, today announced the appointment of Michael R. Stevens, PharmD as Director of Therapeutic Nutrition.

Dr. Stevens joins MusclePharm with over twenty years of well diversified experience in the healthcare and pharmaceutical industry. In addition to his current role as Chief Strategy Officer for Virostatics, Dr. Stevens spent 17 years at Bristol-Myers Squibb, where he held positions of increasing responsibility in the areas of Market Research (Oncology and HIV), Marketing (Oncology), and Medical Affairs (HIV).

“We are extremely pleased to have Dr. Stevens join the MusclePharm team and further strengthen our position in working to add MusclePharm’s Re-con(R) and MuscleGel(R) nutritional supplements to the New York State Medicaid list of prescription medications,” commented Dr. Roscoe Moore, former United States Surgeon General, and Chief Science Director for MusclePharm. “With Dr. Stevens’ extensive experience and assistance, we plan to further MusclePharm’s support of therapeutic nutritional supplementation in the medical community.”

Nutritional Supplementation has long been utilized within the HIV community to maintain and support muscle mass and help strengthen the immune system. Whey protein has been shown through various credible studies to aid in the growth of muscle mass. Unlike other Medicaid available proteins, MusclePharm’s Re-con helps to burn fat while building muscle. This is a factor essential to people living with HIV, especially those on antiviral regimens where unwanted fat may be an issue in those who often battle muscle depletion. MusclePharm’s MuscleGel(R) represents an untapped arena of health and wellness that makes it easy to consume on the go, without the use of liquids or mixing. It’s a gel based protein supplement that enhances the body’s ability to absorb nutrients, ensures a consistent delivery of hydrated nutrients every time, providing a soothing effect to the digestive system, and tastes great.

“I am honored to join MusclePharm in their quest to provide therapeutic, nutritional supplementation,” stated Michael R. Stevens, PharmD. “MusclePharm’s Re-con Nutritional Supplement contains important amino acids, assisting in reaching the higher levels of nutrition required for people living with HIV. I will continue to contribute my diverse experiences to dynamic companies rooted in deep scientific product development and research like MusclePharm, to positively increase the delivery of their products within the medical community.”

Dr. Stevens has served as a member of the Executive Council for the Forum for Collaborative HIV Research — a public-private partnership facilitating discussion on emerging issues in HIV clinical research and working to translate research results into patient care. He has also served on 15 Protocol Committees within the Adult AIDS Clinical Trials Group (ACTG). Michael received his BS Pharmacy and Doctor of Pharmacy degrees from Purdue University.

About MusclePharm(R)

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company’s propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward-looking Statements

MusclePharm Corporation believes the information set forth in this Press Release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Item 2.02 of the Company’s Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.

Contact:

ICR
Investor Contact:
John Mills, Senior Managing Director
310.954.1105

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).

Tags: amazon.com, athletes, body composition, bodybuilders, bodybuilding.com, Brad Pyatt, Cory Gregory, exercise performance, GNC, Jeffrey Stout, Metabolic and Body Composition Laboratory, Michael R Stevens, mlb, MMA, MSLP, muscle function, MusclePharm, NFL, NSF Certified, nutritional supplement, nutritional supplement company, otcbb:MSLP, Sports Nutrition, University of Oklahoma, Vitacost.com, Vitamin Shoppe, Vitamin World

Posted in Top News |

University of Oklahoma to Begin Clinical Research Program on MusclePharm’s Assaults Pre-Workout Performance-Enhancing Product

Tuesday, December 14th, 2010

DENVER, Dec. 14, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, announced today that it will begin a clinical research program with the Metabolic and Body Composition Laboratory in the department of Health and Exercise Science at the University of Oklahoma to determine the effects of MusclePharm Assault(R) beginning in January 2011.

The clinical research program will be led by Jeffrey R. Stout, Ph.D, MusclePharm’s Scientific Advisor, who is an Associate Professor and Director of the OU lab. Stout, along with other faculty in the department, will study the effects of MusclePharm’s products on high-intensity interval training, on aerobic and anaerobic power, repeated sprint ability, body composition, training volume and strength levels.

MusclePharm Assault(R) is rated as a top pre-workout supplement on numerous, premier websites. Scoring 9.2 out of 10 on bodybuilding.com proves Assault(R) to be at the top of its category. With previous assessments and reviews performed by thousands of satisfied customers in conjunction with the research team at the University of Oklahoma, MusclePharm is once again proving themselves as an industry leader.

“We are excited to be working with the University of Oklahoma and such an esteemed team focused on health and exercise science to further understand the results of MusclePharm Assault(R),” commented, Brad Pyatt, MusclePharm’s Chief Executive Officer. “As one of the leading developers and manufacturers of nutritional supplements we continue to focus on safe and scientific product formulations that will benefit the global healthy living and wellness industry as we strive to increase sales and profitability long-term.”

The research team at the University of Oklahoma has conducted and published numerous studies that focus on nutritional interventions on exercise performance, muscle function and body composition, fueling excitement for MusclePharm and the future potential for the product line.

About MusclePharm

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufacturers a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company’s propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward-looking Statements

MusclePharm Corporation believes the information set forth in this Press Release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Item 2.02 of the Company’s Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.

Contact:

ICR
Investor Contact:
John Mills, Senior Managing Director
310.954.1105

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).

Tags: amazon.com, athletes, body composition, bodybuilders, bodybuilding.com, Brad Pyatt, Cory Gregory, exercise performance, GNC, Jeffrey Stout, Metabolic and Body Composition Laboratory, MMA, MSLP, muscle function, MusclePharm, NFL, NSF Certified, nutritional supplement, nutritional supplement company, otcbb:MSLP, Sports Nutrition, University of Oklahoma, Vitacost.com, Vitamin Shoppe, Vitamin World

Posted in Top News |

MusclePharm Raises $1.4 Million Through Convertible Promissory Note & Registration Rights Agreement

Friday, December 10th, 2010

mslp_logo_200x72

DENVER, Dec. 10, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, today announced it has reached an agreement to raise $1.4 million through a convertible promissory note and registration agreement with an accredited investor.

“We are very pleased with the successful completion of the agreement with the investor and believe this capital will support our capital requirements for growth,” commented Brad Pyatt, MusclePharm’s Chief Executive Officer. “We appreciate our investor’s confidence in MusclePharm as we continue to execute our long-term growth strategy.”

This capital raise, combined with the previously released fulfillment agreement with IVitals, further enhances the Company’s overall financial strength for future long-term profitable growth. Management will continue to focus on the development, sales & marketing of MusclePharm’s growing portfolio of nutritional supplement products.

About MusclePharm(R)

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company’s propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward-looking Statements

MusclePharm Corporation believes the information set forth in this Press Release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Item 2.02 of the Company’s Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.

Contact:

ICR
Investor Contact:
John Mills, Senior Managing Director
310.954.1105

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).

Tags: amazon.com, athletes, bodybuilders, bodybuilding.com, Brad Pyatt, convertible promissory note, Cory Gregory, GNC, mlb, MMA, MSLP, MusclePharm, NFL, NSF Certified, nutritional supplement, nutritional supplement company, otcbb:MSLP, registration agreement, Sports Nutrition, Vitacost.com, Vitamin Shoppe, Vitamin World

Posted in Top News |

MusclePharm’s GNC Athlete Tour Hits Pennsylvania and Hawaii GNC Locations in December

Friday, December 3rd, 2010

mslp_logo_200x72

DENVER, Dec. 3, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, announced today that MusclePharm Athletes including UFC Star Rashad Evans, NFL Pittsburgh Steelers Hines Ward and Larry Foote will make appearances at Pennsylvania and Hawaii GNC locations in December.

UFC Star Rashad Evans will visit GNC locations in Hawaii on December 8th to 11th, 2010. Rashad Evans is a former UFC Light Heavyweight Champion. Evans won the heavyweight division of The Ultimate Fighter 2.

NFL Pittsburgh Steelers Hines Ward and Larry Foote will visit GNC locations in Pittsburgh, PA on December 13th to 14th, 2010. Hines Ward is a pro bowl wide receiver and MVP of Super Bowl XL. Larry Foote is a linebacker for the Pittsburgh Steelers where he has earned two Super Bowl rings with the Steelers in Super Bowl XL and Super Bowl XLIII.

December MusclePharm Athletes to Tour the Following GNC locations in December:

UFC Star Rashad Evans in Hawaii

December 8, 2010
SCHOFIELD AFB
SHOFIELD BARRACKS
BUILDING #693 KIOSK
WAHIA WA, HI 96857
(808) 624-0320

December 9, 2010
PMB # 473
4725 BOUGAINEVILLE DR
HONOLULU, HI 96818
(808) 4 22-0355

December 10, 2010
HICKAM AFB
BUILDING 1232
FREEDOM & FOX MAIN EXCHNG
HICKMAN AFB, HI 96853
(808) 423-6420

December 11, 2010
KANEOHE BAY MCB, MOKAPU MALL
MOKAPU MALL
BLDG#6477 SUITE #A119-120
KANEOHE BAY, HI 96863
(808) 254-2600

Pittsburgh Steelers, Larry Foote, in Pittsburgh, PA

December 13, 2010
ROSS PARK MALL
1000 ROSS PARK MALL DRIVE
SPACE LO8
PITTSBURGH, PA 15237
(412) 635-0241

Pittsburgh Steelers, Hines Ward, in Pittsburgh, PA

December 14, 2010
THE STACKS AT THE WATERFRONT
116 WEST BRIDGE ST
HOMESTEAD, PA 15120
(412) 461-1381

“This Athlete Tour will help increase brand awareness for MusclePharm, resulting in better store placement and more GNC locations in near future,” MusclePharm CEO Brad Pyatt said. “This is another way that MusclePharm is setting itself apart from the competition and will continue to make MusclePharm the athlete’s choice for supplementation.”

About MusclePharm

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company’s propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward-looking Statements

MusclePharm Corporation believes the information set forth in this Press Release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Item 2.02 of the Company’s Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.

Contact:

ICR
Investor Contact:
John Mills, Senior Managing Director
310. 954. 1105

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).